A randomized, double-blind trial of canakinumab targeting interleukin-1β innate immunity pathway revealed a significantly lower rate of recurrent cardiovascular events…
A prospective, randomized, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial concluded that a 800 mg/day pharmaceutical-grade Chondroitin sulfate (CS) is superior…
A panel of experts made a strong recommendation against the use of arthroscopy in nearly all patients with degenerative knee…
This website uses cookies.